deltatrials
Unknown NA INTERVENTIONAL 2-arm NCT05567822

The Impact of Esmolol Administration on Postoperative Recovery (esmolol)

The Effect of Intraoperative Esmolol Administration on Postoperative Recovery and Chronic Pain

Sponsor: Aretaieion University Hospital

Updated 5 times since 2022 Last updated: Oct 25, 2022 Started: Oct 1, 2022 Primary completion: Oct 1, 2024 Completion: Oct 1, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05567822, this NA trial focuses on Analgesia and Esmolol and remains ongoing. Sponsored by Aretaieion University Hospital, it has been updated 5 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

Contemporary anaesthesiology requires the quest of ways to restrict the use of opioids, which aim at the alleviation of severe postoperative and chronic pain. This is not only due to the side effects involved but also to the epidemic dimensions their use entails. Esmolol, an extremely short-acting cardioselective antagonist of β1 adrenergic receptors, is effectively used in order to attenuate the stress response and minimize undesirable perioperative hemodynamic changes. More specifically, esmolol has been used effectively to reduce pain during induction of anesthesia with propofol and treat tachycardia and hypertension during laryngoscopy. However, recent studies also highlight a possible antinociceptive and/or analgesic effect of esmolol. Therefore, The aim of this study will be to investigate the effect of a continuous infusion of low dose esmolol on intraoperative and postoperative opioid consumption, as well as on postoperative recovery and chronic pain

Contemporary anaesthesiology requires the quest of ways to restrict the use of opioids, which aim at the alleviation of severe postoperative and chronic pain. This is not only due to the side effects involved but also to the epidemic dimensions their use entails. Esmolol, an extremely short-acting cardioselective antagonist of β1 adrenergic receptors, is effectively used in order to attenuate the stress response and minimize undesirable perioperative hemodynamic changes. More specifically, esmolol has been used effectively to reduce pain during induction of anesthesia with propofol and treat tachycardia and hypertension during laryngoscopy. However, recent studies also highlight a possible antinociceptive and/or analgesic effect of esmolol. Therefore, The aim of this study will be to investigate the effect of a continuous infusion of low dose esmolol on intraoperative and postoperative opioid consumption, as well as on postoperative recovery and chronic pain

Status Flow

~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – present · 17 months · monthly snapshotUnknown~Jan 2026 – present · 3 months · monthly snapshot

Change History

5 versions recorded
  1. Jan 2026 — Present [monthly]

    Unknown NA

  2. Nov 2024 — Present [monthly]

    Unknown NA

    Status: RecruitingUnknown

  3. Sep 2024 — Nov 2024 [monthly]

    Recruiting NA

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting NA

  5. Nov 2022 — Jul 2024 [monthly]

    Recruiting NA

    First recorded

Oct 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aretaieion University Hospital
Data source: Aretaieion University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations